Medexus Pharmaceuticals Inc.
MEDXF
$3.64
-$0.02-0.57%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -393.55% | -206.54% | -107.64% | -83.40% | -26.19% |
| Total Depreciation and Amortization | 18.64% | 35.61% | 56.91% | 53.77% | 42.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.12% | -24.79% | -68.46% | -44.00% | -23.76% |
| Change in Net Operating Assets | -109.75% | -15.44% | 32.92% | -61.91% | -42.42% |
| Cash from Operations | -28.00% | -21.47% | -25.69% | -26.82% | -12.92% |
| Capital Expenditure | 81.52% | 15.85% | -54.55% | -228.00% | -411.11% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | 6.97% | 11.39% | -179.75% | -48.87% | -3.59% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -187.53% | -489.85% | -171.84% | 6.37% | -2,234.72% |
| Cash from Investing | -122.85% | -190.00% | -156.59% | -13.74% | -134.22% |
| Total Debt Issued | -- | -- | 45.45% | -- | -- |
| Total Debt Repaid | 0.08% | -190.69% | -206.53% | 52.77% | 44.14% |
| Issuance of Common Stock | -97.44% | -97.44% | -- | -23.37% | -23.37% |
| Repurchase of Common Stock | -- | -- | 97.87% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 54.63% | 51.36% | 47.94% | 33.78% | 12.99% |
| Cash from Financing | 94.50% | -2,477.01% | 102.28% | 75.25% | 58.61% |
| Foreign Exchange rate Adjustments | -394.12% | 100.00% | 171.90% | -317.65% | 80.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -554.21% | -193.23% | 2,765.79% | 119.22% | 111.98% |